Pharmaceutical company Kaléo will offer up an alternative epinephrine auto-injector to Mylan’s EpiPen starting in 2017, the company announced this week. Desire for such a rival has been high and widespread as patients and lawmakers have thoroughly lambasted Mylan for dramatically hiking the price of its life-saving device. But those seeking solace from the apparent greed of the pharmaceutical industry may not find it in Kaléo or its auto-injector, Auvi-Q.

Auvi-Q has been on the market before and, at times, actually had a higher price tag than Mylan’s EpiPen. Though Auvi-Q’s 2017 price has yet to be set, Kaléo’s drug-pricing track record is similar to Mylan’s. In the past few years, Kaléo has increased the price of a device used to reverse deadly opioid overdoses by more than 650 percent, in fact. And, just like Mylan, Turing, and others, Kaléo claimed that customer assistance programs and discounts would keep high list prices from affecting patients—even though those high list prices can still help drive up overall costs of healthcare.

In an e-mail exchange with Ars, Mark Herzog, vice president of corporate affairs for Kaléo, would not answer direct questions about whether the company would help bring down the inflated costs of epinephrine auto-injectors. Instead, Herzog noted that the company is “working to engage with various stakeholders, including wholesalers, insurance companies, and pharmacy benefit managers, to implement a comprehensive access program for Auvi-Q.” The company’s intention, he added, is that “any patient who needs an epinephrine auto-injector, regardless of insurance coverage, should have affordable access to Auvi-Q.”

Kaléo unveiled Auvi-Q in 2013 and pitched it as a slick substitute for an EpiPen. Designed by twin brothers with deadly food allergies, Auvi-Q is the size of a credit card with the thickness of a sleek smartphone. Whereas EpiPens are more like fat pens, the Auvi-Q can slip into a pants pocket and be discreetly carried around. Also unlike EpiPen, Auvi-Q has a voice prompt system that calmly guides users through the epinephrine injection, which is typically a frantic process to halt a life-threatening allergic reaction.

Kaléo got Auvi-Q on the market by licensing it to Sanofi, a pharmaceutical giant with marketing prowess. At the time of its 2013 debut, the list price of an Auvi-Q two-pack was about $200, which was in line with the price of Mylan’s EpiPen two-packs at the time. By early 2015, Auvi-Q’s price had hiked up to above $500—largely in step with EpiPen’s price but, at points, 10 percent higher. In fact, Mylan even noted Auvi-Q’s escalating price as a factor for raising the price of EpiPens in a letter to Senator Charles E. Grassley (R- Iowa).

But, in October of 2015, Sanofi voluntarily recalled Auvi-Q after reports that the devices weren’t delivering accurate doses of epinephrine. Since then, Kaléo has regained the license for Auvi-Q. The company is feverishly revamping its manufacturing process by automating production and adding more than 100 quality checks.

Meanwhile, its main competitor on the epinephrine auto-injector market, Mylan, has faced unbridled rage from patients, healthcare providers, and lawmakers alike for continuing to raise prices. Currently, the list price of an EpiPen two-pack is $600. Unsurprisingly, Mylan’s profits and executive compensation have skyrocketed in step with the price increases.

While Kaléo now looks to have the opportunity to nobly reenter Auvi-Q onto the market at a price point lower than Mylan’s EpiPen—and Mylan’s upcoming generic version—it may not take that high road. In fact, while Kaléo has been regaining its footing on Auvi-Q, it has dramatically raised the price of another of its products: Evzio, an auto-injector that delivers naloxone, a cheap, decades-old drug that reverses deadly opioid overdoses. In the past two years, Kaléo raised the price of a two-pack of Evzio from $575 to $3,750. The price hikes came amid a nation-wide epidemic of opioid addiction and crisis-level rates of overdoses.

Herzog defended Kaléo’s Evzio pricing saying: “Patients and their caregivers with commercial insurance and a prescription can obtain Evzio with an out-of-pocket cost of $0 even if their insurance does not cover Evzio or they have a high-deductible plan.” Herzog also noted that “the ‘list price’ is not a true net price to anyone.”